As of 2025-07-09, the EV/EBITDA ratio of Blueprint Medicines Corp (BPMC) is -54.29. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. BPMC's latest enterprise value is 8,557.57 mil USD. BPMC's TTM EBITDA according to its financial statements is -157.63 mil USD. Dividing these 2 quantities gives us the above BPMC EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 8.2x - 10.7x | 9.4x |
| Forward P/E multiples | 9.4x - 11.8x | 11.4x |
| Fair Price | (27.10) - (30.13) | (29.37) |
| Upside | -121.1% - -123.5% | -122.9% |
| Date | EV/EBITDA |
| 2025-07-03 | -54.27 |
| 2025-07-02 | -54.21 |
| 2025-07-01 | -54.27 |
| 2025-06-30 | -54.20 |
| 2025-06-27 | -54.17 |
| 2025-06-26 | -54.19 |
| 2025-06-25 | -54.23 |
| 2025-06-24 | -54.23 |
| 2025-06-23 | -54.29 |
| 2025-06-20 | -54.21 |
| 2025-06-18 | -54.18 |
| 2025-06-17 | -54.22 |
| 2025-06-16 | -54.23 |
| 2025-06-13 | -54.11 |
| 2025-06-12 | -54.21 |
| 2025-06-11 | -54.11 |
| 2025-06-10 | -54.11 |
| 2025-06-09 | -54.11 |
| 2025-06-06 | -54.06 |
| 2025-06-05 | -54.09 |
| 2025-06-04 | -54.17 |
| 2025-06-03 | -53.96 |
| 2025-06-02 | -54.04 |
| 2025-05-30 | -43.21 |
| 2025-05-29 | -43.91 |
| 2025-05-28 | -40.73 |
| 2025-05-27 | -42.68 |
| 2025-05-23 | -43.27 |
| 2025-05-22 | -42.79 |
| 2025-05-21 | -43.27 |
| 2025-05-20 | -43.88 |
| 2025-05-19 | -43.15 |
| 2025-05-16 | -43.35 |
| 2025-05-15 | -42.45 |
| 2025-05-14 | -41.63 |
| 2025-05-13 | -42.41 |
| 2025-05-12 | -42.78 |
| 2025-05-09 | -41.50 |
| 2025-05-08 | -42.15 |
| 2025-05-07 | -42.57 |
| 2025-05-06 | -42.31 |
| 2025-05-05 | -43.41 |
| 2025-05-02 | -44.56 |
| 2025-05-01 | -42.35 |
| 2025-04-30 | -38.35 |
| 2025-04-29 | -37.93 |
| 2025-04-28 | -37.95 |
| 2025-04-25 | -37.60 |
| 2025-04-24 | -36.96 |
| 2025-04-23 | -36.84 |